Genetically predicted elevated low-density lipoprotein (LDL) cholesterol, LDL free cholesterol, LDL phospholipids, and LDL total lipids measured by NMR were associated with an increased risk of atrial fibrillation, and LDL is identified as a critical lipoprotein for predicting and treating AF.
Abstract
Background and AimsThe relationship between blood lipids and atrial fibrillation (AF) remains unclear. Nuclear magnetic resonance (NMR) spectroscopy enables the profiling of size-defined lipoproteins and their contained lipid components. This study aimed to analyze the genetic causal relationships between lipoproteins, NMR-measured lipids, and AF, providing insights into the prediction and treatment of AF. Methods and Results. Summary-level data on lipoprotein and lipid concentrations measured by NMR were obtained from the UK Biobank. Summary-level data on AF were sourced from the FinnGen project. Mendelian Randomization (MR) analysis using inverse-variance weighting was employed as the primary analytical method. Genetically predicted elevated low-density lipoprotein (LDL) cholesterol, LDL free cholesterol, LDL phospholipids, and LDL total lipids measured by NMR were associated with an increased risk of AF. MR analyses did not identify robust causal associations between lipids contained in high-density lipoproteins (HDL), intermediate-density lipoproteins (IDL), or very-low-density lipoproteins (VLDL) and AF. Among size-defined LDL particles, elevated lipids of large LDL (L-LDL) were strongly associated with increased risk of AF. Hypertension and coronary heart disease mediated these effects. Genetic variation alleles at ABCG5, LDLR, and PCSK9 genes, which reduce lipid levels, were associated with lower risk of AF. Conclusions Increased lipids contained in LDL were associated with elevated risk of AF. L-LDL particles exhibited a clear association with increased AF risk. LDL is identified as a critical lipoprotein for predicting and treating AF.
All apolipoprotein B (apoB)-containing lipoproteins are causal risk factors for coronary artery disease (CAD). However, triglyceride-rich lipoproteins (TRL) and lipoprotein(a) [Lp(a)] exhibit greater per-particle atherogenicity than low-density lipoprotein (LDL) through mechanisms that remain incompletely underst...
J. Morze, E. Bjornson, Michael Y. Mi et al.· European Heart Journal· 0 citations
Background: The effects of major lipid-lowering therapies on circulating fatty-acid profiles are not fully characterized. We used Mendelian randomization (MR) to examine the effects of major lipid-lowering drug targets, proven to reduce CVD risk, on circulating fatty acids. Methods: We conducted a drug-target MR analys...
Lipid traits are established risk factors for atherosclerotic disease; however, their relationship with intracranial aneurysms and subarachnoid haemorrhage (SAH) remains unclear. Recent Mendelian randomisation (MR) studies have reported inconsistent findings. This study aimed to review the literature and assess the ass...
F. Ewbank, C. Pinn, Benjamin Gaastra et al.· Translational Stroke Researc...· 0 citations
Introduction Apolipoprotein E (APOE) gene significantly affects lipid metabolism and CVD susceptibility, with its isoforms exerting different effects on cholesterol levels and cardiovascular health. Of particular concern is the APOE4 allele, which is linked to dyslipidemia, elevated LDL-C levels, and increased oxidativ...
Chandan das, BA Bora, Nabanita Paul et al.· One Health & Risk Manage...· 0 citations
Abstract INTRODUCTION Plasma high‐density lipoprotein (HDL) varies in size. We examined the associations between HDL subclasses and their lipid composition and incident dementia risk in older adults. METHODS We included 23,790 United Kingdom (UK) Biobank (UKB) and 147 Atherosclerosis Risk in Communities (ARIC) older ad...
Bin-Chong An, S. Ali, Karen Smith et al.· Alzheimer's & Dementia· 0 citations
Atherogenic lipoproteins, including LDL-c and ApoB, are well-established risk factors for atherosclerotic cardiovascular disease (ASCVD). However, whether different lipid markers demonstrate distinct patterns across ASCVD subtypes and age groups remains incompletely defined.
We used data from the UK Bioban...
H. Su, X. Wang, W. Budts et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.